Anticholinergic Drugs Market Size & Share, by Product (Natural, Synthetic Compounds, Semi-Synthetic Compounds); Application (Muscle Spasms, Parkinson Disease, Overactive Bladder, Chronic Obstructive Pulmonary Disease, Irritable Bowel Syndrome); Route Of Administration (Oral, Parenteral, Topical); Distribution Channel (Hospitals, Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2028

  • Report ID: 2561
  • Published Date: Feb 03, 2023
  • Report Format: PDF, PPT

Anticholinergic Drug Market Introduction

Anticholinergic drugs are used to restrict the acetylcholine-provoked neurotransmission in different parts of the body including heart, peripheral nervous system, and other parts. Acetylcholine controls the involuntary functions such as salivation, sweating, digestion, and several others. The drug is used for the treatment of chronic diseases and nervous system disorders such as bladder overactivity, pulmonary disease disorder, irritating bowel syndrome, and several others. 

Anticholinergic Drug Market Size And Forecast

The anticholinergic drug market is anticipated to grow at a significant CAGR during the forecast period, 2020-2028. The technological advancements and increase in the use of disease detection devices are factors estimated to lead to the growth of the market during this period. Further, extensive research and development are predicted to boost the market growth for the drug. The increase in the number of adults, and old aged people is resulting in the increased usage of the drug as well.

The market is segmented by product type, by application, by route of administration, by distribution channel, and by region. On the basis of distribution channel, the market is bifurcated into hospitals and pharmacies. The hospital segment is anticipated to grow at a significant pace as the treatments take place inside the hospitals and the drug is not freely or easily available for use outside hospitals.

Growth Drivers

Extensive Research in the Field of Life Science

The increasing number of researches taking place in the medical sector has improved the quality of medicines and their usage over time. This has aided in understanding the benefits of several drugs in the treatment of several chronic diseases. Further, rising research and development is anticipated to aid in market growth.

The Increasing Number of Adults and Elderly Population

The number of adults and the old-age population is increasing and with that, the problems that are faced in old age are increasing as well. This has resulted in the usage of drugs that help in curing several conditions. Hence, the anticholinergic drugs market is anticipated to grow. 


The field of medicine is evolving and new medicines are developed to improve and fasten the treatment and to improve the quality so the side effects can be minimized. Rapid research and development in the field of medicine along with understanding properties of the drugs and its use in treating the chronic diseases are estimated to result in market evolution. These developments will help the market to grow in the future as better drugs can be developedto treat diseases that are life threatening.


The usage of any drug is restricted as the government creates rules to keep an eye on how and where the drugs are being used. This is predicted to negatively impact the market growth of anticholinergic drugs. Moreover, these drugs have side effects that may result in reduced usage of the drug. To overcome these restraints, the market has to innovate and keep on upgrading.

Market Segmentation

Our in-depth analysis of the anticholinergic drugsmarket includes the following segments:

By Product Type

  • Natural
  • Synthetic Compounds
  • Semi- Synthetic Compounds

By Application

  • Muscle spasms
  • Parkinson’s Disease
  • Overactive Bladder
  • Chronic Obstructive Pulmonary Disease
  • Irritable Bowel Syndrome

By Route of Administration

  • Oral
  • Parenteral
  • Topical

By Distribution Channel

  • Hospitals 
  • Pharmacies

By Region

On the basis of region-wise analysis, the anticholinergic drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.The market in North America is anticipated to hold the largest market share of anticholinergic drugs market. This is the result of supreme quality infrastructure and research opportunities that the region presents. Being technologically advanced, the drugs and medicines can be innovated and developed easily and quickly. The market in Europe region is estimated to hold the second largest share since the region has high cases of diseases such as bladder overactivity and several others, and the healthcare expenditure is rising as well. The market in Asia Pacific region is anticipated to show a slow growth during the forecast period as the infrastructure is not well developed and people are less aware of the diseases related to nervous system and their treatments. The low availability of equipment for testing the diseases is another reason for slow growth.


Anticholinergic drugs market is further classified on the basis of region as mentioned below:

• North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis

• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis

• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis

• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis

• The Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating In The Market


In the News

April 30, 2020: Valneva and Pfizer announced their collaboration for the development of the Lyme disease vaccine, VLA15. This is the only Lyme disease vaccine program that is prevalent presently.  The vaccine is currently in phase 2 and the progress will be revealedby the mid-2020 by the companies.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 2561
  • Published Date: Feb 03, 2023
  • Report Format: PDF, PPT

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying